Atopic dermatitis is what most people who are not medical professionals mean when they talk about “eczema.” There are, however, some other medical conditions that also have the word “eczema” in the ...

and patients only on CNI (cyclosporine or tacrolimus) and glucocorticoids. All patients had an available kidney biopsy within a year of enrollment. The study was registered in the ClinicalTrials.gov ...

Dec. 17, 2024 -- The FDA last week approved Nemluvio for treating moderate to severe atopic dermatitis, a type of eczema, in people aged 12 or older. Nemluvio is to be used with topical ...

The FDA has blessed two previously approved medicines—one a cream and the other an injection—to treat atopic dermatitis (AD). Both products now will be available to a significantly larger ...

"With the FDA’s approval of VTAMA cream in atopic dermatitis for adults and children as young as 2 years old, there is now a therapy that offers the potential for powerful skin clearance with no ...

The FDA has approved Galderma’s Nemluvio (nemolizumab) for the treatment of patients age 12 and older with moderate to severe atopic dermatitis, according to the details of a recently published news ...

The scalp is a very common area for seborrheic dermatitis because it produces a lot of sebum. In babies, seborrheic dermatitis is called cradle cap. With seborrheic dermatitis, you may have an ...

8 IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation and epidermal dysregulation in atopic dermatitis. 2,9-11 “As just one example of our innovative, science-based ...

The US Food and Drug Administration (FDA) has approved nemolizumab for moderate-to-severe atopic dermatitis inadequately controlled with topical therapies in patients aged 12 years and older ...

2,9-11 “As just one example of our innovative, science-based pipeline, Nemluvio is an important and effective new treatment option for patients with atopic dermatitis, where unmet needs remain.

Dermatitis. 2005;16(1):6-21. There has been a report of two patients with localized scleroderma treated with 0.1% topical tacrolimus ointment twice daily under occlusion. There was marked clinical ...